Clinical Outcomes in Patients with COVID-19 Infection During Phase IV Studies of Cladribine Tablets for Treatment of Multiple Sclerosis

Karan R, et al.

Post-Approval Safety of Cladribine Tablets with Particular Reference to COVID-19 Outcomes: An Update

Giovannoni G, et al. 

Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: MAGNIFY-MS Study

Wiendl H, et al. 

Long-Term Efficacy for Patients Receiving Cladribine Tablets in CLARITY/CLARITY Extension: Primary Results from 9–15 Years of Follow-Up in the CLASSIC-MS Study

Giovannoni G, et al.

CLICK-MS: Cladribine Tablets in Patients with Relapsing Multiple Sclerosis After Suboptimal Response to Prior Injectable Disease-Modifying Therapy (Interim Analysis 1)

Miravalle A, et al. 

Post-Approval Safety of Subcutaneous Interferon β-1a in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections

Freedman M, et al. 

The Effect of Evobrutinib, a BTK Inhibitor, on Blood Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis

Kuhle J, et al. 

Concentration of Evobrutinib, a BTK Inhibitor, in Cerebrospinal Fluid During Treatment of Patients with Relapsing Multiple Sclerosis in a Phase II Study

Piasecka-Stryczynska K, et al.

Evobrutinib Efficacy is Maintained Over Two years in an Open-Label Phase II Study Extension in Patients with Relapsing Multiple Sclerosis

Montalban X, et al. 

Safety of Evobrutinib in Patients with Relapsing Multiple Sclerosis is Maintained in a Long-Term Open-Label Extension of a Phase II Study

Montalban X, et al.

Comparing Infection-Related Outcomes by Sex in Patients with Multiple Sclerosis and Matched Controls Using Administrative Claims Data

Bove R, et al. 

Clinical and Economic Burden of Employees Who Are Care Partners of Patients with Multiple Sclerosis

Hendin B, et al. 

Assessing Presence of MS-Related Symptoms as a Proxy for Disease Severity in Multiple Sclerosis Using Administrative Claims Data

Hendin B, et al. 

Patient Practices and Experiences During COVID-19 Among Individuals Across the United States Enrolled in MS LifeLines Patient Support Program

Nicholas J, et al. 

Patient-Provider Communication about Multiple Sclerosis: The MS-SUPPORT Decision Aid

Col N, et al. 

Postpartum Relapse Rates in Women with Relapsing Multiple Sclerosis and the Impact of Disease Modifying Drugs: A Systematic Review

Hellwig K, et al.